Compare Summit Therapeutics Inc (SMMT) vs Stellantis N.V. Common Shares (STLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Stellantis N.V. Common Shares — how do they compare? Summit Therapeutics Inc trades at $15 (market cap $12.07B), while Stellantis N.V. Common Shares trades at $4.27 (market cap $16.20B). The key difference: Stellantis N.V. Common Shares is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Stellantis N.V. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Stellantis N.V. Common Shares for 0 Days on average.
| SMMT | STLA | |
|---|---|---|
Market Cap | $12.07B | $16.20B |
Volume | 4,658,232 | 30,607,418 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $12.12 |
52-Week Low | $12.43 | $4.27 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $11.40B | $35.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today despite recent positive catalysts including a $2 billion strategic investment from AstraZeneca announced September 28, 2026. The stock shows bullish technical signals with strong institutional support, though fundamentals reflect a pre-revenue biotech with significant losses (-$1.08B net income in 2025) and negative ROE of -192.5%. Recent clinical trial collaborations with major pharma partners highlight the company's promising ivonescimab cancer drug pipeline.
The outlook balances substantial upside potential from AstraZeneca's validation and clinical progress against high execution risks typical of developmental biotechs. With 65% analyst buy ratings and a $29.33 consensus target suggesting 89% upside, the stock offers high-risk/high-reward exposure to innovative cancer therapeutics, dependent on successful drug development and regulatory approvals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Stellantis N.V. Common Shares
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →
